pubrio
Paul-Ehrlich-Institut

Paul-Ehrlich-Institut

Germany · Research

Research

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute. The Paul-Ehrlich-Institut, with its more than 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.). www.pei.de/impress

Company Insights
employees-header
employees

Get full access to view complete information

Company Overview

-

Founded

Research

Industry

Germany

Location

69,919

Ranking

500 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Paul-Ehrlich-Institut

Paul-Ehrlich-Institut operates under a [B2B/B2C/B2B2C/SaaS/Product/Service-based] business model. The company generates revenue primarily through [subscription, licensing, project-based services, enterprise contracts, etc.]. Its positioning within the [industry] sector suggests a focus on [value proposition or differentiator].

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​